title: Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
abstract: Glioblastoma multiforme (GBM) is one of the most infiltrating, aggressive, and poorly treated brain tumors. Progress in genomics and proteomics has paved the way for identifying potential therapeutic targets for treating GBM, yet the vast majority of these leading drug candidates for the treatment of GBM are ineffective, mainly due to restricted passages across the blood-brain barrier. Nanoparticles have been emerged as a promising platform to treat different types of tumors due to their ability to transport drugs to target sites while minimizing adverse effects. Herein, we devised a localized strategy to deliver RNA interference (RNAi) directly to the GBM site using hyaluronan (HA)-grafted lipid-based nanoparticles (LNPs). These LNPs having an ionized lipid were previously shown to be highly effective in delivering small interfering RNAs (siRNAs) into various cell types. LNP's surface was functionalized with hyaluronan (HA), a naturally occurring glycosaminoglycan that specifically binds the CD44 receptor expressed on GBM cells. We found that HA-LNPs can successfully bind to GBM cell lines and primary neurosphers of GBM patients. HA-LNPs loaded with Polo-Like Kinase 1 (PLK1) siRNAs (siPLK1) dramatically reduced the expression of PLK1 mRNA and cumulated in cell death even under shear flow that simulate the flow of the cerebrospinal fluid compared with control groups. Next, a human GBM U87MG orthotopic xenograft model was established by intracranial injection of U87MG cells into nude mice. Convection of Cy3-siRNA entrapped in HA-LNPs was performed, and specific Cy3 uptake was observed in U87MG cells. Moreover, convection of siPLK1 entrapped in HA-LNPs reduced mRNA levels by more than 80% and significantly prolonged survival of treated mice in the orthotopic model. Taken together, our results suggest that RNAi therapeutics could effectively be delivered in a localized manner with HA-coated LNPs and ultimately may become a therapeutic modality for GBM.
authors.affiliation: Department of Neurosurgery, Sheba Medical Center , Ramat Gan, Israel.
authors.forename: Zvi R
authors.initials: ZR
authors.lastname: Cohen
authors.forename: Srinivas
authors.initials: S
authors.lastname: Ramishetti
authors.forename: Naama
authors.initials: N
authors.lastname: Peshes-Yaloz
authors.forename: Meir
authors.initials: M
authors.lastname: Goldsmith
authors.forename: Anton
authors.initials: A
authors.lastname: Wohl
authors.forename: Zion
authors.initials: Z
authors.lastname: Zibly
authors.forename: Dan
authors.initials: D
authors.lastname: Peer
mesh_terms: D000818:Animals; D001692:Biological Transport; D018797:Cell Cycle Proteins / Q000172:deficiency; D016923:Cell Death / Q000235:genetics; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D020868:Gene Silencing; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D006820:Hyaluronic Acid / Q000737:chemistry*; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry*; D060787:Neoplasm Grading; D017346:Protein Serine-Threonine Kinases / Q000172:deficiency; D011518:Proto-Oncogene Proteins / Q000172:deficiency; D000067492:RNAi Therapeutics / Q000379:methods*; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D004337:Drug Carriers; D018960:Hyaluronan Receptors; D006820:Hyaluronic Acid; D008055:Lipids; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1
keywords: RNAi; glioma; hyaluronan; lipid-based nanoparticles